| Disease | 65 PATIENTS WITH ADVANCED CANCER WERE ENTERED IN THIS PHASE II TRIAL OF RETINOL. PATIENTS RECEIVED 200,000 UNITS OF RETINOL/ DAY FOR AT LEAST 8 WEEKS, AND WERE EVALUATED AT 4 WEEKS INTERVALS.
TYPES OF CANCER TREATED INCLUDED NON-SMALL CELL LUNG CANCER (17 PATIENTS), MELANOMA (15), ADENOCARCINOMA OF THE COLON (12), AND MISCELLANEOUS TUMORS (17).
OF 55 PATIENTS EVALUABLE FOR RESPONSE, THERE WERE NO COMPLETE RESPONSE, 1 PARTIAL RESPONSE, 5 MIXED RESPONSES, 2 PATIENTS WITH STABLE DISEASE, AND 47 PATIENTS WITH DISEASE PROGRESSION. NO SIDE EFFECTS WERE REPORTED BY 37 OF 60 PATIENTS.
12 PATIENTS REPORTED CNS SYMPTOMOLOGY INCLUDING HEADACHE, CONFUSION, HALLUCINATION, DEPRESSION, DIZZYNESS, PAPILLEDEMA, NAUSEA AND SEIZURE. THE PATIENT WITH SEIZURES WAS FOUND TO HAVE BRAIN METASTASIS.
13 PATIENTS REPORTED MILD CUTANEOUS SYMPTOMS INCLUDING PRURITIS, PATCHY DEPIGMENTATION, AND DRY, SCALLING, OR CHAPPED LIPS. SIDE EFFECTS DISAPPEARED WITHIN 2 WEEKS OF DISCONTINUATION. |